pharmacy · NY
$20–50M revenue specialty pharmacy — NY
asking $5–20Mrevenue $20–50M
opportunity
watch · ndaCluster-8 scorecard
Derived from the captured acquisition signals. Sparse data excludes-and-renormalizes; the regulatory gate is fail-closed.
- Financial attractiveness 51
- AI augmentability —
- Scalability 36
- Strategic fit (needs buyer thesis)—
- Regulatory risk (higher = riskier)47
risk-adjusted multiple ≈ 3.83×
Pre-positioned financing
Banks lend before the cash gap. Gov-receivables deals carry the DAISA/DACA structure automatically.
No financing attached yet.
Request diligence access (NDA) →Captured signals by cluster
Of 371 ontology atoms, this listing has populated:
9/64
Business Characteristics
9/65
Deal and Financial Structure
8/54
Regulatory and Clinical Context
0/75
Marketplace and Platform Features
4/41
Tech and AI Augmentability
0/26
Strategic Fit and Integration
0/26
Sourcing Signal and Deal Intelligence
1/20
Scoring, Flags and Decision Layer (derived)
exclusion-list status: clear